RIPK1 and demyelinating disease: Our study unveils a previously unexplored function of RIPK1 in enhancing the proliferation of OPCs and promoting remyelination by inhibiting RIPK1 kinase activity, and reveals ZJU-37 is a promising new drug candidate for demyelinating diseases, suggesting that promoting proliferation of OPCs is another promising strategy to enhance remyelination.